DrugPatentWatch Database Preview

VELETRI Drug Profile

« Back to Dashboard

When do Veletri patents expire, and when can generic versions of Veletri launch?

Veletri is a drug marketed by Actelion Pharms Ltd and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighteen patent family members in fourteen countries.

The generic ingredient in VELETRI is epoprostenol sodium. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the epoprostenol sodium profile page.

Summary for VELETRI

International Patents:	18
US Patents:	2
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	19
Clinical Trials:	1
Patent Applications:	573
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for VELETRI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VELETRI
Prior Art and Litigation Support	Order Prior Art and Litigation support for VELETRI
DailyMed Link:	VELETRI at DailyMed

Pharmacology for VELETRI

Drug Class	Prostacycline Vasodilator
Physiological Effect	Vasodilation

Medical Subject Heading (MeSH) Categories for VELETRI

Antihypertensive Agents

Platelet Aggregation Inhibitors

Synonyms for VELETRI

(5Z,13E,8R,9S,11R,12R,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid sodium salt

(5Z,9|A,11|A,13E,15S)-6,9-epoxy-11,15-Dihydroxy-prosta-5,13-dien-1-oic Acid Sodium Salt

4K04IQ1OF4

4UA76

61849-14-7

91284-07-0

AC1O4BXH

ACT-385781A

AKOS024457370

BML1-F10

C20H31NaO5

C20H31O5.Na

CAS-61849-14-7

CHEMBL962

Cyclo-Prostin

DSSTox_CID_26617

DSSTox_GSID_46617

DSSTox_RID_81769

DTXSID3046617

EINECS 263-273-7

Epoprostenol sodium

Epoprostenol sodium [USAN:BAN]

Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer

Epoprostenolsodium

Flolan

Floran

HMS1361K18

HMS3648L14

LMHIPJMTZHDKEW-XQYLJSSYSA-M

LS-176206

MolPort-006-132-470

NCGC00167427-01

Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, sodium salt, (5Z,9alpha,11alpha,13E,15S)-

prostacyclin

Prostacyclin sodium

Prostacyclin sodium salt

PROSTAGLANDIN I2 Na

Prostaglandin I2 sodium

Prostaglandin X sodium

SCHEMBL41344

Sodium (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dien-1-oate

sodium (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoate

Sodium (Z)-(3aR,4R,5R,6aS)-hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valerate

sodium (Z)-5-((3aR,4R,5R,6aS)-5-hydroxy-4-((S,E)-3-hydroxyoct-1-enyl)hexahydro-2H-cyclopenta[b]furan-2-ylidene)pentanoate

Sodium prostacyclin

Tox21_112431

U 53,217A

U-53,217A

U-53217A

UNII-4K04IQ1OF4

V0155

US Patents and Regulatory Information for VELETRI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actelion Pharms Ltd	VELETRI	epoprostenol sodium	INJECTABLE;INJECTION	022260-002	Jun 28, 2012		RX	Yes	No
Actelion Pharms Ltd	VELETRI	epoprostenol sodium	INJECTABLE;INJECTION	022260-001	Jun 27, 2008		RX	Yes	Yes
Actelion Pharms Ltd	VELETRI	epoprostenol sodium	INJECTABLE;INJECTION	022260-002	Jun 28, 2012		RX	Yes	No			Y
Actelion Pharms Ltd	VELETRI	epoprostenol sodium	INJECTABLE;INJECTION	022260-001	Jun 27, 2008		RX	Yes	Yes			Y

Paragraph IV (Patent) Challenges for VELETRI

Drugname	Dosage	Strength	RLD	Date
	Injection	0. 5m/vial and1.5 mg/vial

International Patents for VELETRI

Country	Patent Number	Estimated Expiration
Denmark	1993557
Brazil	PI0707488
Slovenia	1993557
Japan	5415771
Cyprus	1117128
European Patent Office	1993557
Portugal	1993557